
Oxford Bioscience Partners - Boston, MA
|
Oxford Bioscience Partners (OBP), established in 1992, is a venture capital firm that provides equity financing and management assistance to emerging, entrepreneurial-driven companies within the life sciences and healthcare sectors. Experienced partners, who bring together deep domain knowledge in life sciences, have established a proven track record of identifying, validating and backing emerging trends and technologies. While willing to consider an investment in a company at almost any stage, OBP brings unique value and expertise to early-stage situations. With approximately $1B of committed capital under management, OBP has invested in over 140 life science companies worldwide, and has successfully leveraged the extensive research, operating, and financial expertise and experience of its team of investment professionals.
Oxford's team of investment professionals has a history of backing leading life science companies, including: SIRNA (acquired by Merck); SOLEXA (acquired by Illumina); ALANTOS (acquired by Amgen); TRUBION (NASDAQ: TRBN); HYPNION (acquired by Eli Lilly); HUMAN GENOME SCIENCES (NASDAQ: HGSI); POWDERMED (acquired by Pfizer); ACADIA (NASDAQ; ACAD); PVT (acquired by Edwards); EXELIXIS (NASDAQ: EXEL); SOSEI (Nikkei: 4565); COHESIVE (acquired by Thermo Fisher); IMPELLA (acquired by Abiomed); STRATAGENE (acquired by Agilent); SANTHERA (SWX:SANN); EXONHIT (EURONEXT: ALEHT); INVERNESS MEDICAL (NYSE: IMA)
|
| |
|
|
 |
|
|
 |
|

October 23, 2008
Advisory Board Meetings
@ Oxford Bioscience Partners 222 Berkeley Street, Suite 1650 Boston, MA 02116
October 24, 2008
Annual Limited Partners Meeting
@ Four Seasons Hotel 200 Boylston Street Boston, MA 02116

September 19, 2007
Oxford Bioscience Partners Promotes Dr. Douglas Fambrough to General Partner
July 6, 2007
Oxford Bioscience Keeps Successes on the QT

June 6, 2007
Amgen to Acquire Alantos Pharmaceuticals, a Private Biotechnology Company in Cambridge, Massachusetts --
more
April 3, 2007
Lilly Announces Completion of Hypnion Acquisition --
more
January 26, 2007
Illumina Announces the Completion of Its Acquisition of Solexa --
more

May 2, 2008
Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals' Nicotinic Alpha-7 Agonist, MEM 3454 --
more
May 1, 2008
Critical Therapeutics Signs Definitive Agreement to Merge with Cornerstone BioPharma --
more
April 30, 2008
Dynogen to Present Positive Clinical Data For DDP225 And DDP733 At Digestive --
more
April 28, 2008
Elixir Pharmaceuticals Announces Issuance of SIRT Patent Covering Development of New Therapies Based on Breakthrough Science --
more
April 21, 2008
Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis --
more
Click here to view more articles
|
|
|
|